CASP3 and brain infarction: HSYA can reduce cerebral infarction volume; decrease the neurological deficit score; increase GSK3β phosphorylation; inhibit the activation of iNOS, NF-κB, and caspase-3; and decrease iNOS, NF-κB, and caspase-3 activity in the penumbra after cerebral I/R.